New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 2, 2013
09:17 EDTS, TEVA, FRX, EBAY, RNF, CTIC, TLM, COF, MKTO, GRPNOn The Fly: Pre-market Movers
HIGHER: Marketo (MKTO), up 10% after upgraded to Conviction Buy at Goldman... Cell Therapeutics (CTIC), up 6% after receiving $5M milestone payment from Teva (TEVA)... eBay (EBAY), up 3.5% after upgraded at SunTrust, positive mention at Stifel... Tailsman (TLM), up 3% after Icahn raises stake in the company, adds representatives to board... Forest Labs (FRX), up 3.5% after announcing restructuring, authorizing $1B share repurchase program... Capital One (COF), up 2% after positive mention in Barron's. LOWER: Groupon (GRPN), down 2.5% following downgrade at Goldman... Rentech Nitrogen (RNF), down 3.5% after confirming incident at Illinois facility... Sprint (S), down 1.3% after downgrade at Macquarie.
News For EBAY;GRPN;TLM;FRX;MKTO;CTIC;TEVA;COF;RNF;S From The Last 14 Days
Check below for free stories on EBAY;GRPN;TLM;FRX;MKTO;CTIC;TEVA;COF;RNF;S the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 8, 2014
09:01 EDTEBAYAmazon SSS grew 26.2% in March, eBay SSS up 17.8%, says ChannelAdvisor
Amazon.com's (AMZN) SSS grew 26.2% in March and eBay's (EBAY) SSS came in at 17.8% for the month, according to ChannelAdvisor. eBay's growth rate was the highest since August 2013, the blog post noted. Reference Link
08:46 EDTTEVATeva announces first approval, launch of generic Lovaza capsules in the U.S.
Teva (TEVA) announces the approval of the generic equivalent to Lovaza in the United States. Teva believes it is first-to-file and thus far is the only company to receive an approval from FDA. Teva plans to commence shipping immediately. Lovaza Capsules, marketed by GlaxoSmithKline (GSK), had annual sales of approximately $1.1B in the United States, according to IMS data as of December 2013.
05:53 EDTEBAYeBay's Magento, PayPal announce partnership with BOXPARK
Subscribe for More Information
April 7, 2014
14:09 EDTTEVASun Pharmaceutical agrees to acquire generic drugmaker Ranbaxy
Subscribe for More Information
07:44 EDTMKTOMarketo to hold a summit
Subscribe for More Information
07:16 EDTEBAYRetailers muscle into competitive mobile payment market, Reuters says
Subscribe for More Information
06:02 EDTMKTOSugarCRM and Marketo collaborate for marketing automation solution
Subscribe for More Information
April 4, 2014
12:13 EDTSSprint launches promotion, offering $650 for customers to switch, BGR reports
Sprint has begun a promotion that will offer people up to $650 to make the switch to their company, reports BGR. Through a forum member on Sprint's fan site S4GRU, the company launched a limited promotion to reimburse new customers up to $350 in early termination fees, as well as a service credit of up to $300 when they trade in their old phones. Reference Link
11:02 EDTSSoftbank said to eye possible M&A opportunities in Europe, Forbes says
Subscribe for More Information
10:45 EDTTEVAMylan rises despite Meda rejecting takeover offer
Mylan (MYL) shares are higher this morning following a Financial Times report of its desire to buy Swedish rival Meda. Subsequent to the story being published, Meda confirmed it had been in talks with Mylan but rejected the company's takeover offer. WHAT'S NEW: The Financial Times reported that Mylan was considering buying Meda, a Swedish drugmaker, in a deal that would create a $23B+ pharmaceuticals business. Mylan reportedly hired advisers to put a deal together for Meda, and though the value of a deal was not noted, sources said Mylan was likely to pay a "significant" premium to Meda's market value, which was $4.5B at the end of trading on Thursday. Mylan's market value currently stands at $18.5B. A combination of the drugmakers would create a company with annual revenues of around $9B, the FT said, noting that would be half the size of generic drug rival Teva (TEVA). WHAT'S NOTABLE: Meda's board of directors confirmed that it was contacted by Mylan regarding a proposal to merge the companies, but the board decided to reject the proposal. Meda said all discussions between the company and Mylan have been terminated "without further actions." ANALYST REACTION: Citigroup upgraded Mylan to Buy from Neutral and raised its price target on the stock to $61 from $52 this morning. The firm cited potential operational and tax benefits from an acquisition of Meda, stating that in addition to expanding Mylan's geographic presence, the deal would increase its presence in specialty, OTC and branded generics. OTHER NEWS: Mylan sued Celgene (CELG) to block that company's efforts to keep generic versions of Revlimid and Thalomid off the market, Reuters reported. PRICE ACTION: Mylan shares are up $2.98, or 5.98%, to $52.84 in mid-morning trading.
08:47 EDTSLenovo, IBM deal investigated by U.S. over Pentagon servers, Bloomberg says
Subscribe for More Information
08:07 EDTSRegulators 'increasingly open' to Sprint, T-Mobile merger, says FBR Capital
Subscribe for More Information
April 3, 2014
14:30 EDTTEVAMylan says USPTO rejects Teva '808 patent reissue application on Copaxone
Subscribe for More Information
14:28 EDTTEVAMylan says USPTO rejects Teva '808 patent reissue application on Copaxone
Subscribe for More Information
12:20 EDTSGoogle considers wireless service in Fiber markets, The Information says
Subscribe for More Information
08:02 EDTTLMCanadian Association of Petro Producers & Scotiabank co-host a symposium
Subscribe for More Information
April 2, 2014
11:48 EDTTEVATeva price target raised to $66 from $57 at Standpoint Research
Subscribe for More Information
11:08 EDTMKTOMarketo to host analyst day
Analyst day to be held in San Francisco on April 8 at 11 am. Webcast Link
07:51 EDTSSeveral communications companies could be bought, says Oppenheimer
Oppenheimer says that the following communications companies could become takeover targets: T-Mobile (TMUS), DirecTV (DTV), DISH (DISH), Level 3 (LVLT), tw telecom(TWTC), and Rackspace (RAX). The firm calls T-Mobile "a prime target," and thinks the company has several potential suitors and is best positioned to benefit from current trends. Oppenheimer expects the major surviving companies in the space to be Comcast (CMCSA), AT&T (T), Verizon (VZ), and Sprint (S). It keeps Outperform ratings on T-Mobile, Rackspace, Comcast, and Verizon. It has Perform ratings on Level 3, tw telecom, and Sprint.
06:21 EDTSSprint volatility elevated at 60
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use